Monitor APUS for filing of 10-K and NYSE listing application. Stock remains halted; any delays in meeting forbearance conditions could trigger default. The settlement reduces immediate governance risk but does not address fundamental liquidity or operating performance.
Price Chart
Executive Summary
APUS filed an 8-K detailing a comprehensive settlement resolving shareholder disputes and a forbearance agreement with its $11M noteholder. The company's stock remains halted on NYSE American, and it faces a June 30, 2026 deadline to regain listing compliance. Lokahi will contribute $4M in working capital and forgive $750k in advances, but the company is under intense operational and regulatory pressure.
Key Facts
- Settlement resolves disputes among APUS, MindWave, Lokahi, and Inscobee; Inscobee grants irrevocable proxy to management.
- Lokahi to transfer $4M working capital to APUS/Newco by April 29, 2026, and forgive $750k advance.
- APUS enters forbearance with Alto Opportunity Master Fund on $11M convertible note; conditions include filing 10-K by April 30, 2026 and regaining NYSE compliance by June 30, 2026.
- Stock trading halted on NYSE American; company must obtain listing approval, effect 1-for-10 reverse stock split, and resume trading by June 30, 2026.
- Board transitions: interim board of three directors, then three new independent directors appointed by Inscobee subject to Menon's approval.
- Newco to be formed as wholly owned subsidiary, to be spun off within 12 months; 90% of net financing proceeds go to MindWave, 10% to Newco.
- Emerson files to dismiss lawsuit against Inscobee; mutual releases among parties.
Financial Impact
Lokahi contributes $4M working capital; note principal $11M; total cash inflow $4M offset by $750k forgiveness.
Risk Factors
- Failure to meet forbearance conditions could trigger note acceleration and default.
- NYSE delisting if listing application is denied or compliance not regained by June 30, 2026.
- Uncertainty over Newco spin-off and valuation.
- Potential dilution from preferred stock conversion and note conversion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-051125 |
| Document: ea0288393-8k_apimeds.htm | 0001213900-26-051125 |
| Document: ea028839301ex10-3.htm | 0001213900-26-051125 |
| Document: ea028839301ex10-2.htm | 0001213900-26-051125 |
| Document: 0001213900-26-051125-index-headers.html | 0001213900-26-051125 |
| Document: 0001213900-26-051125-index.html | 0001213900-26-051125 |
| Document: 0001213900-26-051125.txt | 0001213900-26-051125 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | — | $3.05 (−25.61%) |
Sep 22, 2026 5w ago | 8-K | $2.29 | awaiting T+60 | — | $3.05 (+33.19%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $3.05 (−35.79%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $3.05 (−27.90%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $3.05 (−89.83%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $3.05 (−62.23%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $3.05 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers